Cigna Group(CI)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #499 of 2,879 stocksTOP 25%
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
CI Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Cigna Group (CI), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CI at 66.8/100 on a 32-signal composite quality model, placing it at rank #499 of 2,879 stocks — the top 25% of the AI-ranked universe. CI scores in the top quartile across revenue scale (99.6), revenue growth (76.4), earnings quality (75.4). Areas of concern include free cash flow (39.5), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q1 2026), Cigna Group reports quarterly revenue of $68.5B, net income of $1.7B, an operating margin of 3.4%. Top institutional holders of CI by reported 13-F value include BlackRock,, VANGUARD CAPITAL MANAGEMENT, STATE STREET, based on the most recent SEC filings. CI trades on the NYSE exchange and files with the SEC under CIK 1739940. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Cigna Group directly from SEC EDGAR. Cigna Group's 13F Pro composite quality score has ranged between 8 and 68 since 2021, currently 66.8 — a stable long-term trajectory across 56 quarterly and live scoring snapshots.
What's Driving CI's Business? Latest 10-Q Breakdown
✓ 23/23 datapoints verifiedAI-extracted from Cigna Group's 10-Q filed 2026-04-30 — Q1 2026 (quarter ended March 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Cigna's Q1 2026 net income reached $1.9B (+32% YoY) on total revenues of $68.5B (+5% YoY), driven by pharmacy revenue growth of 11% and improved margins in Cigna Healthcare following the Medicare Advantage divestiture.
Biggest Revenue Drivers
Total revenue: $68.5B+5% YoY
Primarily driven by claims composition changes within Pharmacy Benefit Services operating segment.
Impacted by the HCSC transaction (-30%), offset partly by higher premium rates in ongoing U.S. Healthcare businesses.
Growth in fee-based services within Pharmacy Benefit Services operating segment.
Primarily due to lower average assets from the HCSC transaction.
Largest Expense Items
Reflects changes in claims composition within Pharmacy Benefit Services operating segment.
Driven by the HCSC transaction (-32%), offset partly by higher medical costs in ongoing U.S. Healthcare businesses.
Impacted by the HCSC transaction.
Standard intangible asset amortization.
Margins: Cigna Healthcare's pre-tax margin expanded to 13.2% from 8.9% YoY (+430 bps), driven by improved contributions from U.S. Healthcare reflecting premium rate increases and expense management. The medical care ratio improved 240 bps to 79.8%, benefiting from the HCSC transaction impact.
Watch Items from the Filing
- Accounts receivable allowances increased to $7.7B from $6.8B, with current expected credit loss allowance rising to $228M from $199M, indicating elevated credit risk provisions.
- Strategic optimization program costs totaled $380M pre-tax ($290M after-tax) in Q1 2026, with program-to-date costs of $1.1B; company expects substantially all accrued liability to be paid by end of 2026.
- Medicare Advantage and related businesses were divested to HCSC on March 19, 2025, reducing segment revenues by ~$3.9B YoY; integration and transaction-related costs continue at $35M in Q1.
- Evernorth's pharmacy claim volume declined 2% YoY to 527M claims, partially offset by 6-20% income growth in Specialty and Care Services; claims composition shifts and client-focused initiatives impacted Pharmacy Benefit Services margins.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
Revenue
Q1 2026
$68.5B
Net Income
Q1 2026
$1.7B
Free Cash Flow
Q1 2026
$1.1B
Operating Margin
Q1 2026
3.4%
D/E Ratio
Q1 2026
0.73
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
+57.9% YoYNet Income
Operating Income
+15.9% YoYEPS (Diluted)
+40.8% YoYTotal Assets
+2.0% YoYTotal Debt
-6.6% YoYOp. Cash Flow
+33.5% YoY| Metric | FY 2025 | FY 2021 | FY 2020 | FY 2019 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Revenue | $274.90B +57.9% | $174.07B +8.5% | $160.40B +4.5% | $153.57B +267.3% | $41.81B +4.9% | $39.84B |
| Net Income | $5.96B | — | — | — | — | — |
| Operating Income | $9.20B +15.9% | $7.94B -2.6% | $8.15B +0.9% | $8.08B +104.9% | $3.94B +27.7% | $3.09B |
| EPS (Diluted) | $22.18 +40.8% | $15.75 -31.4% | $22.96 +70.8% | $13.44 +53.2% | $8.77 +22.0% | $7.19 |
| Total Assets | $157.92B +2.0% | $154.89B -0.4% | $155.45B -0.2% | $155.77B +152.2% | $61.76B | — |
| Total Debt | $31.46B -6.6% | $33.67B +2.3% | $32.92B -12.0% | $37.41B +571.6% | $5.57B | — |
| Operating Cash Flow | $9.60B +33.5% | $7.19B -30.5% | $10.35B +9.1% | $9.48B +132.1% | $4.09B +1.5% | $4.03B |
AI Insight: CI Financial Trends
Revenue growth stalled in Q1 2026 after consistent expansion, while operating margins remained compressed despite debt reduction.
• Revenue declined 5.5% QoQ to $68.5B in Q1 2026, reversing 12 consecutive quarters of growth from $60.5B in Q2 2024.
• Operating margin contracted to 3.4% in Q1 2026 from 3.2% in Q4 2025, remaining below the 3.8–4.0% range seen in 2024.
• Total debt declined to $30.9B in Q1 2026 from $34.0B peak in Q3 2025, reducing leverage ratio.
⚠ Operating cash flow turned negative at −$1.9B in Q2 2025, signaling working capital pressure despite revenue growth.
⚠ Q1 2026 revenue miss suggests potential demand softness or business mix headwinds requiring clarification.
AI Insight: CI Ratio Trends
Operating margin remains compressed below 4%, with ROIC stuck near 13% as leverage edges higher.
• OpMargin averaged 3.5% over TTM—lowest since Q2 2024's 4.0%—indicating persistent margin pressure across periods.
• ROIC held between 11.2%–13.8% across all quarters; Q1 2026 at 12.9% shows no net improvement versus two years ago.
• Leverage D/E ratio ticked up to 0.81 in Q3 2025 before settling at 0.73 in Q1 2026, near TTM average of 0.73.
⚠ OpMargin dipped to 3.0% in Q1 2025—the lowest quarterly reading in dataset—raising questions on sustainability.
⚠ ROIC weakness in Q4 2024 (11.9%) and Q1 2025 (11.2%) signals earnings headwinds; recovery incomplete.
Get alerted when CI's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Cigna Group including:
Top Institutional Holders of CI
BlackRock, Inc.
$6.0B22,598,152 shVANGUARD CAPITAL MANAGEMENT LLC
$4.6B17,122,069 shSTATE STREET CORP
$3.3B12,283,141 shMASSACHUSETTS FINANCIAL SERVICES CO /MA/
$3.1B11,595,182 shDODGE & COX
$3.1B11,555,787 shFMR LLC
$2.9B10,957,272 shSanders Capital, LLC
$2.7B10,290,382 shGEODE CAPITAL MANAGEMENT, LLC
$1.6B6,200,342 shVANGUARD PORTFOLIO MANAGEMENT LLC
$1.6B6,163,438 shGQG Partners LLC
$1.6B6,002,448 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $6.0B | 22,598,152 |
| VANGUARD CAPITAL MANAGEMENT LLC | $4.6B | 17,122,069 |
| STATE STREET CORP | $3.3B | 12,283,141 |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | $3.1B | 11,595,182 |
| DODGE & COX | $3.1B | 11,555,787 |
| FMR LLC | $2.9B | 10,957,272 |
| Sanders Capital, LLC | $2.7B | 10,290,382 |
| GEODE CAPITAL MANAGEMENT, LLC | $1.6B | 6,200,342 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1.6B | 6,163,438 |
| GQG Partners LLC | $1.6B | 6,002,448 |
More Healthcare Companies
View all Healthcare →Put CI on your watchlist
Track score changes the day Cigna Group files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is CI a good stock to buy?
13F Pro's AI-powered analysis of Cigna Group (CI) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CI are available on the CI stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own CI?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CI. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Cigna Group's investment landscape.